Growth hormone (GH) replacement in hypopituitary adults with GH deficiency evaluated by a utility-weighted quality of life index: a precursor to cost–utility analysis
2008

Growth Hormone Replacement and Quality of Life in Adults

Sample size: 894 publication Evidence: moderate

Author Information

Author(s): Kołtowska-Häggström Maria, Kind Paul, Monson John P, Jonsson Björn

Primary Institution: KIMS Medical Outcomes, Pfizer Endocrine Care

Hypothesis

How does growth hormone replacement therapy affect the quality of life in adults with growth hormone deficiency?

Conclusion

The study confirmed a significant improvement in quality of life for patients undergoing growth hormone replacement therapy.

Supporting Evidence

  • Patients showed a mean QoL-AGHDAutility gain of 0.32 after treatment.
  • Women had a greater total observed QALY gain than men.
  • QoL-AGHDAutility scores improved significantly during the first year of treatment.

Takeaway

This study shows that giving growth hormone to adults who don't have enough of it can make them feel much better over time.

Methodology

The study used a utility-weighted quality of life index to assess changes in quality of life in GH-deficient adults over 1 to 6 years.

Potential Biases

Potential selection bias due to the nature of the KIMS database, which includes only patients receiving GH treatment.

Limitations

The observational nature of the study may introduce selection bias and limit causal interpretations.

Participant Demographics

The cohort consisted of 894 participants (53% women) with a mean age of 45 years at entry into the study.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1111/j.1365-2265.2007.03010.x

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication